fenfluramine has been researched along with 2019 Novel Coronavirus Disease in 1 studies
Fenfluramine: A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
fenfluramine : A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was undertaken to evaluate the long-term safety and effectiveness of fenfluramine in patients with Lennox-Gastaut syndrome (LGS)." | 9.69 | Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. ( Agarwal, A; Ceulemans, B; Dai, D; Davis, R; Farfel, GM; Galer, BS; Gammaitoni, AR; Gil-Nagel, A; Guerrini, R; Knupp, KG; Lagae, L; Lock, M; Nabbout, R; Nickels, KC; Polega, S; Riney, K; Scheffer, IE; Sullivan, J; Zuberi, SM, 2023) |
| "This study was undertaken to evaluate the long-term safety and effectiveness of fenfluramine in patients with Lennox-Gastaut syndrome (LGS)." | 5.69 | Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. ( Agarwal, A; Ceulemans, B; Dai, D; Davis, R; Farfel, GM; Galer, BS; Gammaitoni, AR; Gil-Nagel, A; Guerrini, R; Knupp, KG; Lagae, L; Lock, M; Nabbout, R; Nickels, KC; Polega, S; Riney, K; Scheffer, IE; Sullivan, J; Zuberi, SM, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Knupp, KG | 1 |
| Scheffer, IE | 1 |
| Ceulemans, B | 1 |
| Sullivan, J | 1 |
| Nickels, KC | 1 |
| Lagae, L | 1 |
| Guerrini, R | 1 |
| Zuberi, SM | 1 |
| Nabbout, R | 1 |
| Riney, K | 1 |
| Agarwal, A | 1 |
| Lock, M | 1 |
| Dai, D | 1 |
| Farfel, GM | 1 |
| Galer, BS | 1 |
| Gammaitoni, AR | 1 |
| Polega, S | 1 |
| Davis, R | 1 |
| Gil-Nagel, A | 1 |
1 trial available for fenfluramine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
Topics: Adolescent; Adult; Anticonvulsants; Child; COVID-19; Fenfluramine; Humans; Lennox Gastaut Syndrome; | 2023 |